Skip to main content

GENES Y VIAS DE SEÑALIZACION EMERGENTES EN EL DESARROLLO Y EL CANCER DE TIROIDES

SAF2016-75531-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

A novel role for the Hippo pathway mediator TAZ in thyroid differentiation

  • Fernández-Méndez, Celia
  • Santisteban, Pilar
Resumen del trabajo presentado al 1st PhD Research Symposium in Health Sciences and Biomedicine, celebrado en la Universidad Autónoma de Madrid el 18 de mayo de 2018., SAF2016-75531-R, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Emerging genes and pathways in thyroid differentiation and tumorigenesis

  • Santisteban, Pilar
Trabajo presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., Thyroid cancer remains the most common endocrine malignancy worldwide and its incidence and mortality has increased steadily over the last four decades., Grants SAF2016-75531-R from MINECO, Spain (FEDER); B2017/BMD-3724 from CAM and GCB14142311CRES from AECC., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Interplay between TGFβ and the Hippo mediator TAZ leads to Sodium-iodide symporter inhibition

  • Fernández-Méndez, Celia
  • Santisteban, Pilar
Resumen del póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., TAZ is a well-known coactivator downstream of the Hippo signaling pathway. Together with its paralogous YAP and the transcription factors of the TEAD family, TAZ plays a key role in the regulation of differentiation, among other cellular processes. Little is known about the involvement of this signaling pathway in the function of the thyroid gland, although TAZ has been described as a coactivator of Pax8 on the thyroglobulin promoter. Pax8 has a predominant role in thyroid differentiation by regulating the transcription of many crucial genes, such as sodium-iodide symporter (NIS). The aim of this work was to study the role of the Hippo pathway, and particularly its mediator TAZ, in NIS expression, and hence in thyroid differentiation. By western blot and immunofluorescence, we show TAZ nuclear expression is promoted by TGFβ signalling through its downstream mediator p38. We demonstrated that nuclear TAZ exerts a marked role as NIS repressor, decreasing its expression levels, affecting its presence in the celular membrane and thus impairing iodide uptake. By chromatin immunoprecipitation (ChIP) and luciferase reporter assays, we demonstrated that TAZ strongly suppresses Pax8 activation of the NIS promoter by decreasing its binding to the NIS Upstream Enhancer (NUE). In fact, the absence of TAZ directly increases Pax8 nuclear levels. RNAi assays of other Hippo effectors were performed in order to check their participation in this process. Although YAP and TEAD1 could have additive effects, TAZ seems to be the main requirement for NIS downregulation. TGFβ role in thyroid differentiation is well establish, however here we describe a novel crosstalk with the Hippo Pathway and its mediator TAZ, remarkably involved in the control of the sodium iodide symporter expression., SAF2016-75531-R, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Antitumor activity of the ERK inhibitor DEL22379 against BRAF-like cells in thyroid cancer

  • Acuña-Ruiz, Adrián
  • Zaballos, Miguel A.
  • Riesco-Eizaguirre, Garcilaso
  • Crespo, Piero
  • Santisteban, Pilar
Resumen del póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., Thyroid cancer is the most prevalent human carcinoma of endocrine origin and its incidence is continuously increasing. Around 80% of all the somatic mutations are accumulated in only five driver genes (BRAF, H/N/K-RAS and RET) which converge in the hyperactivation of the MAPK signalling pathway. Given the central role of this pathway in thyroid tumorigenesis, thyroid cancer research is focused on the identification of new drugs that inhibit the different kinases of the pathway. DEL22379 is an inhibitor of ERK dimerization previously characterized in melanoma and colorectal cancer-derived cell lines as a new approach to partially inhibit ERK activation. It has been reported that ERK dimerization contributes to the activation of ERK cytoplasmic effectors, such as RSK, and enhances malignant cell features. Our objective was to analyse the antitumor effect of the inhibitor of ERK dimerization DEL22379 as a possible therapeutic compound in thyroid cancer. In vitro assays were made with different thyroid cancer cell lines with mutations in BRAF, H/N/K-RAS or RET. To evaluate cell proliferation, migration and invasion; we have used cell cycle, wound healing and matrigel invasion assays, respectively. We also have developed an orthotopic mouse model of anaplastic thyroid cancer by the generation of the 8505c-luc cell line. In vivo tumour progression was monitored by measuring luciferase activity. Treatment with DEL22379 impairs ERK dimers formation in BRAF-like thyroid cells whereas Ras-like cells were unaffected. Unlike melanoma, phosphorylated ERK levels were substantially reduced after treatment with the inhibitor. Inhibition of ERK dimerization and phosphorylation correlated with diminished RSK phosphorylation. We also observed a decrease in cell proliferation, migration and invasion in the anaplastic thyroid cell lines 8505c and OCUT2. DEL22379 treatment significantly reduced tumour growth and formation of lung metastases in an orthotopic mouse model. We propose DEL22379 as a new effective molecule for the inhibition of MAPK signalling and the reduction of cell malignant behaviour, tumour growth and metastasis in vivo, specifically in BRAF-like thyroid tumours. It promises to be another step forward in the achievement to cure thyroid cancer., This work was supported by grants SAF2016-75531-R from Ministerio de Economía y Empresa (MINECO), Spain and PI14/01980 from ISCIII, Spain (FEDER) and GCB14142311CRES from Asociación Española contra el Cancer (AECC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Role of the IQGAP1 scaffold protein in thyroid cancer

  • Carrasco-López, Carlos
  • Zaballos, Miguel A.
  • Santisteban, Pilar
Resumen del póster presentado al 6th Symposium on Biomedical Research: Advances and Perspectives in Molecular Endocrinology "In Homage to Gabriella Morreale", celebrado en el Instituto de Investigaciones Biomédicas Alberto Sols (IIBM-CSIC) el 31 de mayo de 2019., The IQGAP family of scaffold proteins comprises three members which have been described to interact with numerous proteins in several biological processes and participate in the signaling cascade of multiple pathways. Among these proteins IQGAP1 has been the most deeply studied, having characterized its function as a scaffold protein in the MAPK pathway and its interaction with actin leading to regulation of the cytoskeleton. Because of these functions it has been studied in multiple malignancies, where it has been assigned a tumorigenic effect. We have studied IQGAP1 expression using different stablished cell lines of human thyroid carcinomas. Our results indicate that these carcinoma cell lines have variable levels of IQGAP1 but in general these levels are higher when compared to the normal thyroid cell line control. The results obtained are in agreement with the TCGA and Oncomine databases. Using IQGAP1 silenced cell lines we tried to elucidate how this protein was affecting tumor hallmarks such as proliferation, invasion, cell migration and epithelial mesenchymal transition. The effects of silencing IQGAP1 were different depending on the cell line and the oncogenic signature. While in some of them silencing produced an increase in the migration rate of the cells, others had the opposite behavior. We also found these differences when studying EMT markers such as E-cadherin and N-cadherin. Furthermore, cell viability was unaffected by IQGAP1 silencing and consequently the size of the primary tumor was not altered when cells were xenografted in a chicken embryo model. Importantly IQGAP1 silencing greatly decreased the ability of the tumor cells to intravasate and metastasize to distant organs such as lungs and brain. Further studies will focus on trying to discover the underlying mechanisms responsible for the differences observed between cell lines. Our results indicate a role forIQGAP1 in thyroid tumorigenesis and underscore the importance of defining the oncogenic signature and particularities of a given tumor type in order to design effective therapeutic strategies., This work was supported by grants SAF2016-75531-R from MINECO, Spain and PI14/01980 from ISCIII, Spain (FEDER); B2017/BMD-3724 from CAM and GCB14142311CRES from AECC., Peer reviewed